Ivabradine Zentiva (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node by binding to HCN channels. This inhibition slows the spontaneous depolarisation of pacemaker cells, resulting in a reduced heart‑rate without compromising myocardial contractility, blood pressure, or ventricular repolarisation.

The dosage of Ivabradine Zentiva is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical status and tolerance. The prescriber determines the appropriate starting dose, titration schedule and maintenance dose, following local labeling and clinical guidelines.

Safety of ivabradine during pregnancy and lactation has not been established. The product is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Ivabradine Zentiva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for heart‑rate reduction in angina and heart failure is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting beta‑adrenergic receptors, so it does not influence blood pressure or contractility. This makes it useful when beta‑blockers are contraindicated, not tolerated, or already maximally dosed.

Store Ivabradine Zentiva tablets at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Ivabradine Zentiva is taken orally as a tablet, usually with or without food. The tablet should be swallowed whole with a glass of water. Dosing times are typically spaced evenly (e.g., twice daily) as directed by the prescriber to maintain consistent heart‑rate control.

The most serious adverse events include severe bradycardia that may cause syncope, atrial fibrillation, high‑grade atrioventricular block, and rare cases of permanent visual loss. Patients should be instructed to report symptoms such as dizziness, fainting, palpitations, or sudden changes in vision promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, uncontrolled hypotension, or a resting heart rate below 50 beats per minute. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.